This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Clarus Therapeutics Holdings マネジメント

マネジメント基準チェック /04

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M

Aug 18

Clarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies

Dec 01

CEO（最高経営責任者

Clarus Therapeutics Holdings CEOがいない、あるいは彼らに関するデータがない。

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Dudley	Founder & Director	19yrs	US$2.48m	0.0088% $ 5.0
Steve Stark	Vice President of Commercial Analytics & Operations	no data	データなし	データなし
Rozita Passarella	Vice President of Marketing	no data	データなし	データなし
Mike Cleveland	Vice President of Sales	1.1yrs	データなし	データなし
Jay Newmark	Chief Medical Officer	1.4yrs	データなし	データなし
James Holloway	Senior Vice President of Manufacturing & Supply	1.4yrs	データなし	データなし
Lawrence Perkins	Chief Restructuring Officer	no data	データなし	データなし

1.4yrs

平均在職期間

経験豊富な経営陣: CRXT.Q's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

This company is no longer active

Clarus Therapeutics Holdings マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022

Clarus Therapeutics Holdings, Inc. Announces Appointment of Steven Bourne as Principal Accounting Officer, Effective August 31, 2022

Clarus Therapeutics Holdings, Inc. Announces Resignation of Joseph Hernandez from Board of Directors and Committees

No independent directors

Recent updates

First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022

Nasdaq to Delist Common Stock of Clarus Therapeutics Holdings

Motion for Asset Sale Filed by Clarus Therapeutics Holdings, Inc.

Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from S&P TMI Index

Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from NASDAQ Composite Index

Clarus Therapeutics Holdings Receives a Staff Determination Letter from Nasdaq

Clarus Therapeutics Holdings Inc Contemplates Bankruptcy

Clarus Therapeutics Holdings, Inc. Announces Appointment of Steven Bourne as Principal Accounting Officer, Effective August 31, 2022

Clarus Therapeutics GAAP EPS of -$0.24 beats by $0.06, revenue of $4.05M misses by $0.92M

Clarus Therapeutics Holdings, Inc. announced delayed 10-Q filing

Clarus Therapeutics Holdings, Inc. Announces Resignation of Joseph Hernandez from Board of Directors and Committees

Clarus Therapeutics Receives Written Notice from the Staff, or the Staff, of the Listing Qualifications Department of the Nasdaq Stock Market

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Clarus Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$7.20

No longer forecast to breakeven

Clarus Therapeutics Holdings, Inc. has completed a Composite Units Offering in the amount of $34.497461 million.